At the annual meeting of the European Society of Cardiology, being held this weekend in Madrid, new cardiac care guidelines call for a more uniform, simplified and accessible approach to | The latest ...

Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis (PBC), clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and ...

Fosun Pharma has penned its third inflammatory disease pact in three weeks, plucking up China rights to a clinical-stage treatment from Accro Bioscience. | Fosun Pharma has penned its third ...

Eight months after Sanofi’s former chief medical officer, Dietmar Berger, M.D., departed, the French drugmaker has selected Marcia Kayath, M.D., Ph.D., to fill the role. Kayath will start in her new ...

Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first ...

Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a ...

Oral therapy Relyvrio, which Amylyx is again referring to as AMX0035, was tested in progressive supranuclear palsy (PSP), a ...

The setback marks the second this year for Telix’s radiodiagnostic portfolio, after the Australian developer received a complete response letter in April for a separate PET agent aimed at brain cancer ...

A new foundation from the estate of late Microsoft co-founder Paul Allen has launched with a set of four research grant ...

As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline.  | As obesity ...

The National Cancer Institute (NCI) is ending its support for a 26-year-old push to advance clinical trials for children with ...

Philips has begun rolling out a major update to its cardiovascular ultrasound systems, incorporating a host of imaging ...